CSV February 23, 2023 through February 23, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
IPRATROPIUM ASSAY/		*USP38–NF33*	3932	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First*	Line 4 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
BROMIDE	*Procedure*						*Supplement to USP39–NF34*	*Analysis*: Change ($C_{20}H_{30}BrNO_3 \cdot H_2O$) to: ($C_{20}H_{30}BrNO_3$)
RIBAVIRIN TABLETS	IMPURITIES/*Organic Impurities, Procedure 1*	*USP38–NF33*	5162	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Footnote e of *Table 2*: Change 1-?-D-Ribofuranosyl-1*H*-1,2,4-triazole-3-carboxamide. to: 1-?-D-Ribofuranosyl-1*H*-1,2,4-triazole-5-carboxamide.
RIVASTIGMINE TARTRATE CAPSULES	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP38–NF33*	5215	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 2 of USP Rivastigmine Related Compound B RS: Change *N*,*N*-Dimethylcarbamic acid-3-[1-(dimethylamino)ethyl]phenyl ester. to: (*RS*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								)?3?[1?(Dimethylamino)ethyl]phenyl dimethylcarbamate.
CHLORPHENIRAMINE MALEATE	SPECIFIC TESTS/*Optical Rotation, Specific Rotation <781>*	*Second Supplement to USP38–NF33*	Online	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 1: Delete *Specific Rotation*
BOVINE SERUM	APPENDIX 1	*USP38–NF33*	719	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 2 of bullet 1 of International Regulations and Guidance Documents in second paragraph: Change http://www.emea.europa.eu/pdfs/human/bwp/026895en.pdf to: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003684.pdf

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND Line 2 of bullet 2 of International Regulations and Guidance Documents in second paragraph: Change http://www.emea.europa.eu/pdfs/human/bwp/179302en.pdf to: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/WC500003675.pdf AND Line 3 of bullet 3 of International Regulations and Guidance Documents in second paragraph:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change http://www.emea.europa.eu/pdfs/vet/iwp/074300en.pdf to: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500004575.pdf AND Delete bullet 4 of International Regulations and Guidance Documents in second paragraph AND Line 2 of bullet 5 of International Regulations and Guidance Documents in second paragraph: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								http://www.emea.europa.eu/pdfs/human/bwp/TSE%20NFG%20410-rev2.pdf to: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003712.pdf AND Line 1 of bullet 6 of International Regulations and Guidance Documents in second paragraph: Change Terrestrial animal health code 2007. Available at http://www.oie.int/eng/normes/mcode/code2007/anc-en_summ

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ary.htm. to: Terrestrial animal health code. Available at http://www.oie.int/doc/ged/D10905.pdf.
HYDROXYZINE PAMOATE ORAL SUSPENSION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP38–NF33*	3817	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Delete USP Hydroxyzine Hydrochloride RS
NOREPINEPHRINE BITARTRATE	CHEMICAL INFORMATION	*USP38–NF33*	4582	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 6: Change [69815-49-2]. to: [108341-18-0].
RIVASTIGMINE TARTRATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP38–NF33*	5213	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 2 of USP Rivastigmine Related Compound B RS: Change *N*,*N*-Dimethylcarbamic acid-3-[1-(dimethylamino)ethyl]phenyl ester. to: (*RS*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								)?3?[1?(Dimethylamino)ethyl]phenyl dimethylcarbamate.
VALGANCICLOVIR HYDROCHLORIDE	*Assay*	*USP38–NF33*	5729	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 4 of *Procedure*: Change Calculate the percentage, on the anhydrous and solvent-free basis, of $C_{14}H_{22}N_6O_5 \cdot HCl$ to: Calculate the percentage of valganciclovir hydrochloride ($C_{14}H_{22}N_6O_5 \cdot HCl$) AND Line 8 of *Procedure*: Change $100[(r_U / W_U)(C_F)(100) /(100 ? S_U)]$ to: $100[(r_U/W_U)(C_F)(100)]$

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND Line 12 of *Procedure*: Change C_F is the correction factor; and S_U is the total percent of solvent and water in the test sample. to: and C_F is the correction factor. AND Line 16 of *Procedure*: Change (W_S / R_S)[(100 ? S_S) /100] to: (W_S/R_S)/100 AND Line 18 of *Procedure*: Change R_S is the area response (sum of two peaks for valganciclovir

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								diastereomers) obtained from the *Standard preparation*; and S_S is the total percent of solvent and water in USP Valganciclovir Hydrochloride RS. to: and R_S is the area response (sum of two peaks for valganciclovir diastereomers) obtained from the *Standard preparation*.
MUCOSAL DRUG PRODUCTS—PRODUCT QUALITY TESTS	PRODUCT QUALITY TESTS FOR MUCOSAL DRUG PRODUCTS /*General Necessary*	*USP38–NF33*	76	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 1 of footnote 2: Change http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3B_R2/Step4/Q3B_R2_Guide

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Tests/Impurities							line.pdf. to: http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html.
CHLOROXYLENOL	IMPURITIES/*Limit of Tetrachloroethylene*	*USP38–NF33*	2774	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Row 3 of Column 1 of *Table 2*: Change 210 to: 70 Row 3 of Column 2 of *Table 2*: Change 0 to: 35
METHOHEXITAL	CHEMICAL INFORMATION	*USP38–NF33*	4316	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 5: Change [18652-93-2] to: [151-83-7]
RIVASTIGMINE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP38–NF33*	5212	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 2 of USP Rivastigmine Related Compound B RS: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Nor impurity; (*S*)-3-[1-(Dimethylamino)ethyl]phenyl dimethylcarbamate. to: Nor impurity (racemic mixture); (*RS*)?3?[1?(Dimethylamino)ethyl]phenyl dimethylcarbamate.
ROPIVACAINE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP38–NF33*	5225	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 2 of USP Ropivacaine Related Compound B RS: Change (*R*)-ropivacaine hydrochloride monohydrate; (*R*)-(?)-1-propylpiperidine-2-carboxylic acid (2,6-dimethylphenyl)-amide hydrochloride monohydrate.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: (*R*)-Ropivacaine hydrochloride monohydrate; (*R*)-(+)-1-propylpiperidine-2-carboxylic acid (2,6-dimethylphenyl)-amide hydrochloride monohydrate.
BROMPHENIRAMINE MALEATE	SPECIFIC TESTS/*Optical Rotation, Specific Rotation <781>*	*USP38–NF33*	2475	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 1: Delete *Specific Rotation* AND Line 1 of *Sample*: Change 100 mg/mL in water to: 100 mg/mL in water at 20°
IPRATROPIUM BROMIDE	DEFINITION	*USP38–NF33*	3932	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 2: Change ($C_{20}H_{30}BrNO_3 \cdot H_2O$) to: ($C_{20}H_{30}BrNO_3$)
OXAZEPAM	SPECIFIC	*USP38–NF33*	4683	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First*	Line 1: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	TESTS/*pH <791>*						*Supplement to USP39–NF34*	*Sample solution*: 20 mg/mL to: *Sample*: A suspension of 1 g of Oxazepam in 50 mL water
RIVASTIGMINE TARTRATE	IMPURITIES/*Organic Impurities/Procedure 1*	*USP38–NF33*	5213	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Footnote c of *Impurity Table 1*: Change (*S*)-3-[1-(Dimethylamino)ethyl]phenyl dimethylcarbamate (rivastigmine related compound B). to: (*S*)?3?[1?(Dimethylamino)ethyl]phenyl dimethylcarbamate (racemic mixture is rivastigmine related compound B).
SODIUM	SPECIFIC	*USP38–NF33*	6877	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First*	Line 6 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
STEARYL FUMARATE	TESTS/*Fats and Oils, Saponification Value <401>*						*Supplement to USP39–NF34*	*Analysis*: Change Rinse the condenser with two 10-mL portions of 70% alcohol, add phenolphthalein TS, to: Rinse the condenser with 10 mL of 70% alcohol, followed by three 10-mL portions of water, collecting the rinsings in the flask. Cool, rinse the sides of the flask with two 10-mL portions of 70% alcohol, add phenolphthalein TS,
ANTIBIOTICS—MICROBIAL ASSAYS	APPENDIX 1. FORMULAS FOR MANUAL CALCULATION	*USP38–NF33*	133	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 19: Change b = [(4 × 17.222) + (2 ×

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	S OF REGRESSION AND SAMPLE CONCENTRATION							16.511) ? (2 × 14.989) ? (4 × 14.020)]/{5[ln(7.81)] ? ln(3.2)} = 3.551 to: b = [(4 × 17.222) + (2 × 16.511) ? (2 × 14.989) ? (4 × 14.020)]/{5[ln(7.81) ? ln(3.2)]} = 3.551
ETHOTOIN	*Related compounds/ Procedure*	*USP38–NF33*	3415	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 11:Change weight, in mg, on the anhydrous basis, of the portion of Ethotoin taken; to: weight, in mg, of the portion of Ethotoin taken;
NALOXONE HYDROCHLORIDE	IMPURITIES/ *Noroxymorphone Hydrochloride [(?)-4,5?-Epoxy-3,14-Dihydroxy*	*USP38–NF33*	4486	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Add *Application volume*: 5 µL

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	morphinan-6-one-hydrochloride] and Other Impurities/ Chromatographic system							
METHOTREXATE	IMPURITIES/*Organic Impurities*/*Procedure 1: Related Compounds*	*USP38–NF33*	4318	31-Jul-2015	1-Aug-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 15 of *Analysis*: Change methotrexate related compound E free acid to: methotrexate related compound E free base AND Line 8 of the second variable definition list for *Analysis*: Change methotrexate related compound E free acid to: methotrexate

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								related compound E free base AND Row 5 of Column 1 of *Impurity Table 1*: Change Methotrexate related compound E free acid[c] to: Methotrexate related compound E free base[c]
TETRACAINE HYDROCHLORIDE FOR INJECTION	*Chromatographic purity*	*USP38–NF33*	5508	31-Jul-2015	1-Aug-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 1: Change Dissolve an accurately weighed quantity of *Tetracaine Hydrochloride for Injection* in water to obtain a test solution containing 50 mg per mL, and proceed as directed in the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								test for *Chromatographic purity* under *Tetracaine*, beginning with “Prepare a Standard solution.” to: Dissolve an accurately weighed quantity of Tetracaine Hydrochloride for Injection in water to obtain a test solution containing 50 mg per mL. Prepare a Standard solution of 4-(butylamino) benzoic acid in methanol containing 0.2 mg per mL. Apply separate 5-µL portions of the test solution

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								and the Standard solution to a suitable thin-layer chromatographic plate (see *Chromatography <621>*) coated with a 0.25-mm layer of chromatographic silica gel mixture. Develop the plate in a suitable chromatographic chamber containing a solvent system consisting of a mixture of chloroform, methanol, and isopropylamine (98:7:2) until the solvent front has moved about three-fourths of the length of the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								plate. Remove the plate from the chamber, and dry in a current of warm air. Examine the plate under shor t-wavelength UV light: any spot obtained from the test solution, other than the principal spot, is not more intense than the principal spot obtained from the Standard solution (0.4%), and the sum of the intensities of any such spots is not greater than 0.8%.
METHACRYLIC ACID AND METHYL METH ACRYLATE COPOLYMER	ASSAY/ *Procedure*	*USP38–NF33*	6755	31-Jul-2015	1-Aug-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 3 of *Acceptance criteria*: Delete on the dried basis AND

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Line 5 of *Acceptance criteria*: Delete on the dried basis
BIOTECHNOLOGY-DERIVED ARTICLES -- POLYACRYLAMIDE GEL ELECTROPHORESIS	INTRODUCTION	*Harmonization (Official December 01, 2015)*	Online	31-Jul-2015	1-Aug-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	A paragraph before the *Introduction* was deleted: This chapter provides guidance and procedures used for characterization of biotechnology-derived articles by polyacrylamide gel electrophoresis. Portions of the chapter that are not harmonized with the other two pharmacopeias are marked by the symbol ?. This chapter is harmonized

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								with the corresponding chapter in *JP* and *EP*. Other characterization tests, also harmonized, are shown in *Biotechnology-Derived Articles—Amino Acid Analysis <1052>*, *Biotechnology-Derived Articles—Capillary Electrophoresis <1053>*, *Biotechnology-Derived Articles—Isoelectric Focusing <1054>*, *Biotechnology-Derived Articles—Peptide Mapping <1055>*, and *Biotechnology-Derived Articles—Total*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Protein Assay <1057>.
AMOXICILLIN TABLETS FOR ORAL SUSPENSION	ASSAY/ *Procedure*	*USP38–NF33*	2225	31-Jul-2015	1-Aug-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 6 of *Analysis*: Change Result = $(r_U/r_S) \times (C_S/C_U) \times P \times (1/F) \times 100$ to: Result = $(r_U/r_S) \times (C_S/C_U) \times P \times F \times 100$
TETRACAINE HYDROCHLORIDE INJECTION	*Identification*	*USP38–NF33*	5507	31-Jul-2015	1-Aug-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 1 of *A*: Change It responds to *Identification* test *B* under *Tetracaine Hydrochloride*. to: Dissolve 100 mg in 10 mL of water, and add 1 mL of potassium thiocyanate solution (1 in 4): a crystalline precipitate is formed. Recrystallize

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the precipitate from water, and dry at 80° for 2 hours: it melts between 130° and 132°.
METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER	ASSAY/ *Procedure*	*USP38–NF33*	6753	31-Jul-2015	1-Aug-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 1 of *Acceptance criteria*: Delete on the dried basis
DOXAZOSIN MESYLATE	IM PUR ITIES/*Organic Impuri ties*/*Analysis*	*First Supplement to USP38–NF33*	7387	31-Jul-2015	1-Aug-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 3 of the variable definition list: Change r_S = peak response of each impurity from the *Standard solution* to: r_S= peak response of each impurity or doxazosin mesylate (for calculating unspecified impurities) from the *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution AND Line 5 of the variable definition list: Change C_S = concentration of USP Doxazosin Mesylate RS in the *Standard solution* (mg/mL) to: C_S= concentration of the corresponding USP Doxazosin Related Compound RS or USP Doxazosin Mesylate RS (for calculating unspecified impurities) in the *Standard solution* (mg/mL)
METOLAZONE	ASSAY/	*USP38–NF33*	4368	31-Jul-2015	1-Aug-2015	*USP40–NF35*	*First*	Change the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TABLETS	*Procedure*						*Supplement to USP39–NF34*	subsection *Standard solution:* 5 µg/mL of USP Metolazone RS in methanol to: *Standard stock solution:* 0.25 mg/mL of USP Metolazone RS in methanol *Standard solution:* 5 µg/mL of USP Metolazone RS in *Mobile phase* from *Standard stock solution* AND Line 2 of *Sample solution*: Change of metolazone from the *Sample stock solution* in methanol to: of metolazone

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								in *Mobile phase* from the *Sample stock solution*
TETRACAINE HYDROCHLORIDE IN DEXTROSE INJECTION	*Identification*	*USP38–NF33*	5509	31-Jul-2015	1-Aug-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 1 of *B*: Change It responds to *Identification* test *C* under *Tetracaine Hydrochloride*. to: A solution of 100 mg in 5 mL of water meets the requirements of the tests for *Chloride <191>*.
PURIFIED STEARIC ACID	ASSAY/*Procedure*/*System suitability*/*Suitability requirements*	*USP38–NF33*	6919	31-Jul-2015	1-Aug-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 2 of *Relative standard deviation*: Change six replicate injections of *Sample solution*; to: six replicate injections;

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ESTRADIOL AND NORETHINDRONE ACETATE TABLETS	IMPURITIES/*Organic Impurities/Procedure/System suitability*	*USP38–NF33*	3385	31-Jul-2015	1-Aug-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 2 of the *Note*: Change 1.0, 1.4, and 3.0, to: 1.0, 1.1, and 1.7,
TETRACAINE HYDROCHLORIDE FOR INJECTION	*Identification*	*USP38–NF33*	5508	31-Jul-2015	1-Aug-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 1 of *B*: Change It responds to *Identification* test *B* under *Tetracaine Hydrochloride*. to: Dissolve 100 mg in 10 mL of water, and add 1 mL of potassium thiocyanate solution (1 in 4): a crystalline precipitate is formed. Recrystallize the precipitate from water, and dry at 80° for 2 hours: it melts

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								between 130° and 132°.
METHACRYLIC ACID AND METHYL METH ACRYLATE COPOLYMER	DEFINITION	*USP38–NF33*	6755	31-Jul-2015	1-Aug-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Methacrylic acid units in Methacrylic Acid and Methyl Methacrylate Copolymer are NLT 27.6% and NMT 50.6%, calculated on the dried basis. to: Methacrylic acid units in Methacrylic Acid and Methyl Methacrylate Copolymer, previously dried, are NLT 27.6% and NMT 50.6%.
STEARIC ACID	ASSAY/ *Procedure/System suitability/Suitability requirements*	*Harmonization (Official May 01, 2015)*	Online	31-Jul-2015	1-Aug-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 3 of *Relative standard deviation*: Change peaks (from six replicate injections of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Sample solution); to: peaks, from six replicate injections;
OXAPROZIN TABLETS	IMPURITIES/*Organic Impurities/System suitability/Suitability requirements*	*USP38–NF33*	4681	31-Jul-2015	1-Aug-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Delete the subsection *Signal-to-noise ratio:* NLT 3000
METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER	DEFINITION	*USP38–NF33*	6753	31-Jul-2015	1-Aug-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 4: Change Methacrylic acid units in Methacrylic Acid and Ethyl Acrylate Copolymer are NLT 46.0% and NMT 50.6%, calculated on the dried basis. to: Methacrylic acid units in Methacrylic Acid and Ethyl Acrylate

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Copolymer, previously dried, are NLT 46.0% and NMT 50.6%.
ALMOTRIPTAN MALATE	IM PURITIES/*Limit of Almotriptan Related Compound D and Almotriptan N-Dimer*	*First Supplement to USP38–NF33*	7325	31-Jul-2015	1-Aug-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 1of *Internal standard solution*: Change 4-hydroxy-phenylpiperidine to: 4-hydroxy-4-phenylpiperidine
REAGENTS	REAGENT SPE	*USP38–NF33*	1841	29-May-2015	1-Jun-2015	*USP39–NF34*	*USP39–NF34*	Line 1: Change [10028-22-5] to: [15244-10-7]
CEFIXIME	*Ferric Sulfate* CHEMICAL INFORMATION	*USP38–NF33*	2665	29-May-2015	1-Jun-2015	*USP39–NF34*	*USP39–NF34*	Line 9: Change [79350-37-1]. to: [125110-14-7]. Anhydrous [79350-37-1].
IDARUBICIN HYDROCHLORIDE INJECTION	SPECIFIC TESTS/ *Constituted Solution*	*USP38–NF33*	3834	29-May-2015	1-Jun-2015	*USP39–NF34*	*USP39–NF34*	Delete the *Constituted Solution* test.
METHYLPHENIDATE HYDRO	ADDITIONAL REQUIREMENT	*USP38–NF33*	4348	29-May-2015	1-Jun-2015	*USP39–NF34*	*USP39–NF34*	Line 3 of USP Methylphenidat

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CHLORIDE EXTENDED-RELEASE TABLETS	S/*USP Reference Standards <11>*							e Related Compound A RS: Change 255.75 to: 255.74
SODIUM CETOSTEARYL SULFATE	IMPURITIES/*Limit of Free Cetostearyl Alcohol*	*USP38–NF33*	6868	29-May-2015	1-Jun-2015	*USP39–NF34*	*USP39–NF34*	Line 5 of *Analysis*: Change Result = $100(r_A + r_B) \times W_{IS} \times (SA_{(corr)} \times W)$ to: Result = $100(r_A + r_B) \times W_{IS}/(S_{A(corr)} \times W)$ AND Line 12 of *Analysis*: Change $SA_{(corr)}$ to: $S_{A(corr)}$
TELMISARTAN TABLETS	IDENTIFICATION/*A. Ultraviolet Absorption <197U>*	*Revision Bulletin (Official December 01, 2014)*	Online	29-May-2015	1-Jun-2015	*USP39–NF34*	*USP39–NF34*	Line 3: Change as obtained in the test for *Dissolution*. to: as obtained in the test for

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Dissolution, Test 1.
GOOD DISTRIBUTION PRACTICES FOR BULK PHARMACEUTICAL EXCIPIENTS	SECTION 2: QUALITY, ORGANIZATION, AND DOCUMENTATION/*2.8 Contract Activities*	*USP38–NF33*	1396	29-May-2015	1-Jun-2015	*USP39–NF34*	*USP39–NF34*	Footnote 2: Change http://whqlibdoc.who.int/trs/WHO_TRS_917_annex2.pdf (Accessed June 30, 2011) to: http://who.int/medicines/areas/quality_safety/quality_assurance/GoodtradeDistributionPracticesTRS917Annex2.pdf?ua=1 (Accessed March 2, 2015)
BENZOYL PEROXIDE GEL	IMPURITIES/*Organic Impurities*	*USP38–NF33*	2399	29-May-2015	1-Jun-2015	*USP39–NF34*	*USP39–NF34*	Line 18 of *Standard solution D*: Change hydrous benzoyl peroxide ($C_{14}H_{10}O_4$). to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								anhydrous benzoyl peroxide ($C_{14}H_{10}O_4$).
CUPRIC SULFATE	ASSAY/ *Procedure/Titrimetric system*	*USP38–NF33*	2965	29-May-2015	1-Jun-2015	*USP39–NF34*	*USP39–NF34*	Line 1 of *Endpoint detection*: Change Potentiometric to: Visual
METHYLPHENIDATE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP38–NF33*	4345	29-May-2015	1-Jun-2015	*USP39–NF34*	*USP39–NF34*	Line 3 of USP Methylphenidate Related Compound A RS: Change 255.75 to: 255.74

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 24
- Page 25
- Page 26
- Page 27
- Page 28
- Page 29

- Page 30
- Page 31
- Page 32
- …
- Next page Next ›
- Last page Last »